<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927117</url>
  </required_header>
  <id_info>
    <org_study_id>SHAIER2021IRB02</org_study_id>
    <nct_id>NCT04927117</nct_id>
  </id_info>
  <brief_title>Evaluation of Visual Acuity in Myopic Cataract Patients Using Trifocal Intraocular Lens</brief_title>
  <official_title>Evaluation of Binocular Visual Acuity in Myopic Cataract Patients Using Trifocal Intraocular Lens : a 2 Years Prospective, Observational, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aier School of Ophthalmology, Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aier School of Ophthalmology, Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PanOptix trifocal IOL is a new trifocal intraocular lens which is proved to provide good&#xD;
      range of vision for distance, intermediate and near and good visual quality in cataract&#xD;
      patients with normal axial length. But whether it can get the same visual quality in myopia&#xD;
      is still unknown&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are a few publications of multi-focal IOLs on Chinese patients with high myopia. From&#xD;
      published papers, it is known that performance of multifocal IOLs is satisfied in myopic&#xD;
      patients. However there is no publication to investigate PanOptix in moderate and high myopic&#xD;
      patients. So it is imperative to demonstrate good performance of PanOptix in those special&#xD;
      patients. The purpose of this study is to assess visual performance and patient satisfaction&#xD;
      after the implantation of PanOptix in myopic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Axial length (AL)</measure>
    <time_frame>1 minute</time_frame>
    <description>Measured using the partial coherence laser interferometry (IOLMaster, Carl Zeiss Meditec, Germany)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected distance visual acuity</measure>
    <time_frame>10 minutes</time_frame>
    <description>Uncorrected distance visual acuity (4m) were measured using the reading table model of the Early Treatment Diabetic Retinopathy Study charts (ETDRS; Vector Vision, Ltd, Greenville, OH, USA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected near visual acuity</measure>
    <time_frame>10 minutes</time_frame>
    <description>Uncorrected near visual acuity (40cm) were measured using the reading table model of the Early Treatment Diabetic Retinopathy Study charts (ETDRS; Vector Vision, Ltd, Greenville, OH, USA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected intermediate visual acuity</measure>
    <time_frame>10 minutes</time_frame>
    <description>Uncorrected intermediate visual acuity (60cm) were measured using the reading table model of the Early Treatment Diabetic Retinopathy Study charts (ETDRS; Vector Vision, Ltd, Greenville, OH, USA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>contrast sensitivity</measure>
    <time_frame>30 minutes</time_frame>
    <description>Binocular contrast sensitivity was measured at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the functional acuity contrast test(Test SV-1000) of the CC-100 HW 5.0 Series system</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cataract</condition>
  <condition>Myopia</condition>
  <condition>Intraocular Lens</condition>
  <arm_group>
    <arm_group_label>high myopic group (group1:AL≥26.0 mm)</arm_group_label>
    <description>axial length≥26.0 mm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>age-matched control group</arm_group_label>
    <description>axial length&lt;26.0mm</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Myopic Cataract Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Axial myopic patients（Refractive condition match the axial length after eliminate the&#xD;
             nuclear cataract induced myopia factor）&#xD;
&#xD;
          2. Corneal astigmatism &lt;1.0D (IOL-Master 500/700, Carl Zeiss Meditec, Jena, Germany);&#xD;
&#xD;
          3. Eyes with pupil diameter&gt;2.5 mm (Photopic) and&lt;6 mm (Mesopic) (Pentacam HR, Oculus&#xD;
             Optikgerate GmbH);&#xD;
&#xD;
          4. Eyes with angle kappa&lt;0.50 mm (Pentacam HR);&#xD;
&#xD;
          5. Eyes with corneal spherical aberration&lt;0.50 (Pentacam HR)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Irregular corneal astigmatism&#xD;
&#xD;
          2. Any retinal disease, macular disease(Including myopic MD and retinal diseases) could&#xD;
             affect VA, glaucoma and other severe intraocular diseases&#xD;
&#xD;
          3. Moderate-severe dry eye&#xD;
&#xD;
          4. Amblyopia（BCDVA&lt;0.7 before cataract appears）&#xD;
&#xD;
          5. Patients having difficulties with examinations or 3 months' follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xu Chen</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Aier Eye Hospital China.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu Chen</last_name>
    <phone>+8613601762646</phone>
    <email>Francois.chenxu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xu Chen</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Chen</last_name>
      <phone>+8613601762646</phone>
      <email>Francois.chenxu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Adilamu Abulimiti</last_name>
      <phone>+8618616770462</phone>
      <email>adila0716@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kohnen T, Herzog M, Hemkeppler E, Schönbrunn S, De Lorenzo N, Petermann K, Böhm M. Visual Performance of a Quadrifocal (Trifocal) Intraocular Lens Following Removal of the Crystalline Lens. Am J Ophthalmol. 2017 Dec;184:52-62. doi: 10.1016/j.ajo.2017.09.016. Epub 2017 Sep 18.</citation>
    <PMID>28923587</PMID>
  </reference>
  <results_reference>
    <citation>García-Pérez JL, Gros-Otero J, Sánchez-Ramos C, Blázquez V, Contreras I. Short term visual outcomes of a new trifocal intraocular lens. BMC Ophthalmol. 2017 May 17;17(1):72. doi: 10.1186/s12886-017-0462-y.</citation>
    <PMID>28514944</PMID>
  </results_reference>
  <results_reference>
    <citation>Alió JL, Plaza-Puche AB, Alió Del Barrio JL, Amat-Peral P, Ortuño V, Yébana P, Al-Shymali O, Vega-Estrada A. Clinical outcomes with a diffractive trifocal intraocular lens. Eur J Ophthalmol. 2018 Jul;28(4):419-424. doi: 10.1177/1120672118762231. Epub 2018 Apr 5.</citation>
    <PMID>29619883</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myopia</keyword>
  <keyword>visual acuity</keyword>
  <keyword>monocular defocus curve</keyword>
  <keyword>binocular contrast sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

